Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and...
Covered in this story
Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wells Fargo: $250 → $300 by Aug 2027 · Overweight via Investing.com
- Guggenheim: $244 → $288 by Aug 2027 · Buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.